Evaxion
Business Services · Denmark · 11-50 Employees
View Company Info for Free
Overview
Headquarters
F Dr Neergaards Vej 5, Hoersholm, North ...Phone Number
+45 31319753Website
www.evaxion.aiRevenue
$7.5 MillionStock Symbol
EVAXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Evaxion
Evaxion Biotech is a pioneering TechBio company that utilizes its advanced AI platform, AI-Immunology, to discover, design, and develop personalized vaccines for cancer and infectious diseases. The company focuses on decoding the human immune system to create novel vaccine candidates tailored to specific disease signatures. With a multidisciplinary team and state-of-the-art facilities, Evaxion aims to rapidly identify therapeutically relevant vaccine targets, enhancing the efficiency of vaccine development. Their innovative approach positions them at the forefront of the biotechnology industry, addressing the growing demand for effective treatments against critical diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Evaxion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Evaxion recently announced quarterly report
Evaxion, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Evaxion has recently received funding, and reach out quickly before it becomes old news!
Click to see if Evaxion had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Evaxion has new funding data
Check out if Evaxion is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Evaxion
Product Launch: Get notified when Evaxion launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Evaxion as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Evaxion is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Evaxion is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Evaxion.
Evaxion financials insights
Gather financial insights about Evaxion, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Private Equity
$40M
Evaxion Tech Stack
A closer look at the technologies used by Evaxion
See more technologies
Most Recent Scoops
Promotion
Executive Move
Birgitte Rønø, Chief Scientific Officer, has assumed the additional role of Chief Operating Officer.
Executive Moves, Promotion
Project
reported two-year Phase 2 data for EVX-01, its personalized peptide-based cancer vaccine in advanced melanoma, presented at ESMO in October. The data showed a 75% objective response rate, 25% complete response rate, and 92% of responders remained in response at the two-year mark.
Medical Research, Pharmaceuticals, Clinical Operations
Partnership
Evaxion has entered into a collaboration with The Gates Foundation on the design of a new polio vaccine. The company reports significant interest in its platform and pipeline programs from multiple parties.
Partnership, Product Development, Pharmaceuticals
Award
Evaxion has been recognized by The Galien Foundation for AI advances in human health. This recognition honors the company's AI-Immunology platform.
Award, Artificial Intelligence
Project
Pharmaceuticals, Artificial Intelligence
Evaxion News & Media
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
Evaxion A/S (EVAX) Q2 2026 Earnings Call August 20, 2026 8:30 AM EDTCompany ParticipantsHelen Tayton-Martin - Chief Executive OfficerBirgitte Rono - Chief...Evaxion announces business update and second quarter 2026 financial results
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results.Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
COPENHAGEN, Denmark, August 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it pipeline of cancer vaccine programs with EVX-05 against the deadly brain cancer glioblastoma.Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening of the Nasdaq CM.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Evaxion
Sign Up For FreeTo access detailed company insights
Evaxion Biotech is a pioneering TechBio company that utilizes its advanced AI platform, AI-Immunology, to discover, design, and develop personalized vaccines for cancer and infectious diseases. The company focuses on decoding the human immune system to create novel vaccine candidates tailored to specific disease signatures. With a multidisciplinary... Read More
